FDA Shouldn't Require Monitoring Of Third Parties In REMS, Industry Says

FDA's requirements for Risk Evaluation and Mitigation Strategies should focus on sponsors' activities and not the behavior of third parties, industry tells the agency in comments on a draft guidance

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet